Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca2+ entry1

Cancer Research

Volumn 60, Issue 4, 2000, Pages 1002-1008

  Haverstick, Doris M ^a   Heady, Tiffany N ^b   Macdonald, Timothy L ^b   Gray, Lloyd S ^a,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; TH 1177; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM; CELL DIVISION; DRUG DESIGN; HUMANS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; PYRROLIDINES;

EID: 0034652479     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Russel, P. J., Bennett, S., and Stricker, P. Growth factor involvement in progression of prostate cancer. Clin. Chem., 44: 705-723, 1998.
2. Steiner, M. S. Role of peptide growth factors in the prostate: a review. Urology, 42: 99-110, 1993.
3. Lamm, M. L., Sintich, S. M., and Lee, C. A proliferate effect of transforming growth factor-β1 on a human prostate cancer cell line, TSU-Pr1. Endocrinology, 139: 787-790, 1998.
4. Moretti, R. M., Marelli, M. M., Dondi, D., Poletti, A., Martini, L., Motta, M., and Limonta, P. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J. Clin. Endocrinol. Metab., 81: 3930-3937, 1996.
5. Tennant, M. K., Thrasher. J. B., Twomey, P. A., Drivdahl, R. H., Birnbaum, R. S., and Plymate, S. R. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol Metab., 81: 3774-3782, 1996.
6. Gerdes, M. J., Dang, T. D., Larsen, M., and Rowley, D. R. Transforming growth factor-β1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology, 139: 3569-3577, 1998.
7. Exton, J. H. Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Annu. Rev. Pharmacol. Toxicol., 36: 481-509, 1996.
8. Berridge, M. J., and Irvine, R. F. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature (Lond.), 312: 315-321, 1984.
9. Meldolesi, J. Bringing cell growth research together. Nat. Med., 1: 512-513, 1995.
10. Alessandro, R., Masiero, L., Liotta, L. A., and Kohn, E. C. The role of calcium in the regulation of invasion and angiogenesis. In Vivo, 10: 153-160, 1996.
11. Benzaquen, L. R., Brugnara, C., Byers, H. R., Gattoni-Celli, S., and Halperin, J. A. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat. Med., 1: 534-540, 1995.
12. Densmore, J. J., Szabo, G., and Gray, L. S. A voltage-gated calcium channel is linked to the antigen receptor in Jurkat T lymphocytes. FEBS Lett., 312: 161-164, 1992.
13. 2+ entry in Jurkat T cells. Cell Calcium, 23: 361-368, 1998.
14. CRAC has no apparent role. Am. J. Physiol., 271: C1494-C1503, 1996.
15. 2+ channel antagonists. J. Med. Chem., 26: 775-785, 1983.
16. 2+ channel antagonists. Trends Pharmacol. Sci., 13: 256-262, 1992.
17. Putney, J. W., Jr. A model for receptor-regulated calcium entry. Cell Calcium, 7: 1-12, 1986.
18. 2+ influx in human T lymphocytes. Mol. Biol. Cell, 4: 173-184, 1993.
19. Kohn, E. C., Alessandro, R., Spoonster, J., Wersto, R. P., and Liolta, L. A. Angiogenesis: role of calcium-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 92: 1307-1311, 1995.
20. 2+-ATPaSe. Proc. Natl. Acad. Sci. USA, 87: 2466-2470, 1990.
21. Takemura, H., Hughes, A. R., Thastrup, O., and Putney, J. W., Jr. Activation of calcium entry by the tumor promoter thapsigargin in parotid acinar cells. Evidence that an intracellular calcium pool, and not an inosilol phosphate, regulates calcium fluxes at the plasma membrane. J. Biol. Chem., 264: 12266-12271, 1989.
22. Fang, W-G., Pirnia, F., Bang, Y-J., Myers, C. E., and Trepel, J. B. P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. J. Clin. Investig., 89: 191-196, 1992.
23. Means, A. R. Calcium, calmodulin, and cell cycle regulation. FEBS Lett., 94: 1-4, 1994.
24. Takuwa, N., Zhou, W., and Takuwa, Y. Calcium, calmodulin, and cell cycle progression. Cell. Signalling, 95: 93-104, 1995.
25. Berridge, M. J., Bootman, M. D., and Lipp, P. Calcium: a life and death signal. Nature (Lond.), 395: 645-648, 1998.
26. Furuya, Y., Lundmo, P., Short, A. D., Gill, D. L., and Isaacs, J. T. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res., 54: 6167-6175, 1994.